National Research Corp (NRCIA) is Trading Higher on Unusual Volume for January 11

Equities Staff |

National Research Corp (NRCIA) experienced unusually high volume on Jan. 11, as the stock gained 4.26% to a closing price of $14.19. The stock saw 26,102 shares trade hands over the course of the day on 263 trades. Given that the stock’s average daily volume over the last month has been 16,354 shares a day, this represents a pretty substantial spike over the norm.

National Research Corp has a P/B ratio of 3.99. It also has a P/E ratio of 21. The stock has traded between $17.42 and $10.72 over the last 52-weeks, its 50-day SMA is now $15.37, and its 200-day SMA $13.81.

National Research Corp implements surveys and performs analysis. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

Headquartered in Lincoln, NE, National Research Corp has 397 employees and is currently under the leadership of CEO Michael D. Hays.

For a complete fundamental analysis analysis of National Research Corp, check out’s Stock Valuation Analysis report for NRCIA. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…